EA200700876A1 - Агенты, специфически связывающие ангиопоэтин-2 - Google Patents

Агенты, специфически связывающие ангиопоэтин-2

Info

Publication number
EA200700876A1
EA200700876A1 EA200700876A EA200700876A EA200700876A1 EA 200700876 A1 EA200700876 A1 EA 200700876A1 EA 200700876 A EA200700876 A EA 200700876A EA 200700876 A EA200700876 A EA 200700876A EA 200700876 A1 EA200700876 A1 EA 200700876A1
Authority
EA
Eurasian Patent Office
Prior art keywords
angiopoetin
specifically binding
agents specifically
antibodies
fragments
Prior art date
Application number
EA200700876A
Other languages
English (en)
Other versions
EA011866B1 (ru
Inventor
Джонатон Даниел Олайнер
Кевин Грэхэм
Original Assignee
Амджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Амджен Инк. filed Critical Амджен Инк.
Publication of EA200700876A1 publication Critical patent/EA200700876A1/ru
Publication of EA011866B1 publication Critical patent/EA011866B1/ru

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Раскрыты специфические связывающие агенты, такие как полностью человеческие антитела, которые связывают ангиопоэтин-2. Раскрыты также фрагменты тяжёлых цепей, фрагменты лёгких цепей и участки, определяющие комплементарность (CDR), в составе антител, а также способы получения и применения этих антител.
EA200700876A 2004-10-19 2005-10-19 Агенты, специфически связывающие ангиопоэтин-2 EA011866B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents
PCT/US2005/037911 WO2006045049A1 (en) 2004-10-19 2005-10-19 Angiopoietin-2 specific binding agents

Publications (2)

Publication Number Publication Date
EA200700876A1 true EA200700876A1 (ru) 2007-10-26
EA011866B1 EA011866B1 (ru) 2009-06-30

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700876A EA011866B1 (ru) 2004-10-19 2005-10-19 Агенты, специфически связывающие ангиопоэтин-2

Country Status (10)

Country Link
JP (2) JP2008520188A (ru)
CN (1) CN101495513B (ru)
BR (1) BRPI0518209A (ru)
EA (1) EA011866B1 (ru)
IL (1) IL182279A0 (ru)
MA (1) MA29015B1 (ru)
MX (1) MX2007004247A (ru)
RU (2) RU2404992C2 (ru)
SG (1) SG156668A1 (ru)
ZA (1) ZA200704020B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520188A (ja) * 2004-10-19 2008-06-19 アムジエン・インコーポレーテツド アンジオポエチン−２特異的結合物質
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
JP2014532053A (ja) * 2011-09-30 2014-12-04 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 治療用ペプチド
WO2013112438A1 (en) * 2012-01-23 2013-08-01 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
MX368099B (es) * 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
CN106075448A (zh) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用
CN106512006A (zh) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用
CN109096368B (zh) * 2018-09-30 2021-07-20 华南理工大学 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用
KR102527315B1 (ko) * 2019-02-25 2023-05-03 주식회사 파멥신 항-Ang2 항체 및 이의 용도
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
CN116265487A (zh) * 2021-12-16 2023-06-20 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540165A (ja) * 1999-03-26 2002-11-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔｉｅ２レセプターアクチベーターによる血管透過性の調節
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
CA2473970C (en) * 2001-10-12 2013-05-28 Monosolrx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
JP2008520188A (ja) * 2004-10-19 2008-06-19 アムジエン・インコーポレーテツド アンジオポエチン−２特異的結合物質

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
US9534007B2 (en) 2012-12-21 2017-01-03 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity

Also Published As

Publication number Publication date
RU2007118670A (ru) 2008-12-27
CN101495513B (zh) 2014-08-06
EA011866B1 (ru) 2009-06-30
MA29015B1 (fr) 2007-11-01
CN101495513A (zh) 2009-07-29
JP2008520188A (ja) 2008-06-19
SG156668A1 (en) 2009-11-26
IL182279A0 (en) 2007-07-24
ZA200704020B (en) 2008-06-25
JP2011207882A (ja) 2011-10-20
MX2007004247A (es) 2007-06-12
BRPI0518209A (pt) 2008-11-04
RU2404992C2 (ru) 2010-11-27
RU2010132956A (ru) 2012-02-10

Similar Documents

Publication Publication Date Title
EA200700876A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
RS28904A (en) Angiopoietin-2 specific binding agents
EA200400526A1 (ru) Агенты, специфически связывающиеся с человеческим ангиопоэтином-2
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
EA201070888A1 (ru) Антитела и их производные
NO2017032I1 (no) bezlotoksumab
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
EA200800812A1 (ru) Композиции антитела против cd3
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
EP1912674B8 (en) Bispecific single chain fv antibody molecules and methods of use thereof
WO2005112564A3 (en) Germline and sequence variants of humanized antibodies and methods of making and using them
EA200802168A1 (ru) Гуманизированное антитело к с-kit
MY144925A (en) Il-17 antagonistic antibodies
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
TW200635946A (en) Binding proteins specific for human matriptase
EA200801172A1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
WO2008133641A3 (en) Antibodies directed to gpnmb and uses thereof
WO2006058890A3 (en) Method of producing antibodies
MX360580B (es) Autoanticuerpos humanos anti-alfa-sinucleina.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU